The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Wilson, Cornelia M.; Magnaudeix, Amandine; Naves, Thomas; Vincent, François; Lalloué, Fabrice; Jauberteau, Marie‐Odile

doi:10.2174/1389200216666150812121902

Cited by 22 publications

(12 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbon nanotubes (CNT) are made of graphene cylinders with open ends. The number of graphene layers can determine the flexibility of the carrier: fewer layers mean more flexibility [114]. CNTs are used as a chemotherapy drug, RNA, and protein delivery agent and also as biosensors [115].…”

Section: Nanocarriers Nanoparticles and Vectorsmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

2019

View full text Add to dashboard Cite

Treatment of certain central nervous system disorders, including different types of cerebral malignancies, is limited by traditional oral or systemic administrations of therapeutic drugs due to possible serious side effects and/or lack of the brain penetration and, therefore, the efficacy of the drugs is diminished. During the last decade, several new technologies were developed to overcome barrier properties of cerebral capillaries. This review gives a short overview of the structural elements and anatomical features of the blood–brain barrier. The various in vitro (static and dynamic), in vivo (microdialysis), and in situ (brain perfusion) blood–brain barrier models are also presented. The drug formulations and administration options to deliver molecules effectively to the central nervous system (CNS) are presented. Nanocarriers, nanoparticles (lipid, polymeric, magnetic, gold, and carbon based nanoparticles, dendrimers, etc.), viral and peptid vectors and shuttles, sonoporation and microbubbles are briefly shown. The modulation of receptors and efflux transporters in the cell membrane can also be an effective approach to enhance brain exposure to therapeutic compounds. Intranasal administration is a noninvasive delivery route to bypass the blood–brain barrier, while direct brain administration is an invasive mode to target the brain region with therapeutic drug concentrations locally. Nowadays, both technological and mechanistic tools are available to assist in overcoming the blood–brain barrier. With these techniques more effective and even safer drugs can be developed for the treatment of devastating brain disorders.

show abstract

Section: Nanocarriers Nanoparticles and Vectorsmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

2019

View full text Add to dashboard Cite

show abstract

“…[92][93][94][95][96] Initially, SLN-or MSLN-loaded bioactive compounds were given intranasally or intravenously, and these showed extensive bioavailability in the brain, thereby preventing inflammation and further progression of AD. [97][98][99][100][101] Quercetin-loaded SLN with a particle size of about 200 nm was studied for its efficacy in the AD model, and it showed excellent delivery of quercetin to the brain with a higher antioxidative effect in brain cells. 102 The transport of bioactive compounds to the brain occurs through the endocytosis of the brain capillaries, and these compounds can thereby cross the blood-brain barrier.…”

Section: Anti-alzheimer's Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

127

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

“…By virtue of their ability to target specific tissues and anatomical structures, nanoscale drug delivery systems have emerged as valuable tools for the treatment of many serious illnesses, including cancer, genetic disorders, and degenerative or infectious diseases . However, prior to reaching diseased tissue, therapeutic nanocarriers must first overcome a diverse set of obstacles.…”

Section: Introductionmentioning

confidence: 99%

Preventing Obstructions of Nanosized Drug Delivery Systems by the Extracellular Matrix

Tomasetti

Breunig

2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Although nanosized drug delivery systems are promising tools for the treatment of severe diseases, the extracellular matrix (ECM) constitutes a major obstacle that endangers therapeutic success. Mobility of diffusing species is restricted not only by small pore size (down to as low as 3 nm) but also by electrostatic interactions with the network. This article evaluates commonly used in vitro models of ECM, analytical methods, and particle types with respect to their similarity to native conditions in the target tissue. In this cross-study evaluation, results from a wide variety of mobility studies are analyzed to discern general principles of particle-ECM interactions. For instance, cross-linked networks and a negative network charge are essential to reliably recapitulate key features of the native ECM. Commonly used ECM mimics comprised of one or two components can lead to mobility calculations which have low fidelity to in vivo results. In addition, analytical methods must be tailored to the properties of both the matrix and the diffusing species to deliver accurate results. Finally, nanoparticles must be sufficiently small to penetrate the matrix pores (ideally R < 0.5; d = particle diameter, p = pore size) and carry a neutral surface charge to avoid obstructions. Larger (R >> 1) or positively charged particles are trapped.

show abstract

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Cited by 22 publications

References 180 publications

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Preventing Obstructions of Nanosized Drug Delivery Systems by the Extracellular Matrix

Contact Info

Product

Resources

About